Advanced

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : a multicenter IMWG study

Dimopoulos, M. A.; Kastritis, E; Terpos, E; Nahi, H; Goldschmidt, H.; Hillengass, J; Leleu, X; Beksac, Meral; Alsina, M and Oriol, Albert, et al. (2017) In Leukemia 31. p.2443-2448
Abstract

Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T0 was 3.1 years. The median number... (More)

Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T0 was 3.1 years. The median number of lines of therapy before T0 was 4 (range 3-13). The median overall survival (OS) from T0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.Leukemia advance online publication, 16 June 2017; doi:10.1038/leu.2017.138.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Journal Article
in
Leukemia
volume
31
pages
2443 - 2448
publisher
Nature Publishing Group
external identifiers
  • scopus:85031678437
  • wos:000414215400018
ISSN
1476-5551
DOI
10.1038/leu.2017.138
language
English
LU publication?
yes
id
8b12a008-d256-4956-a9ef-6eb26cbb9f35
date added to LUP
2017-10-03 10:38:37
date last changed
2018-04-29 04:42:38
@article{8b12a008-d256-4956-a9ef-6eb26cbb9f35,
  abstract     = {<p>Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T0 was 3.1 years. The median number of lines of therapy before T0 was 4 (range 3-13). The median overall survival (OS) from T0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.Leukemia advance online publication, 16 June 2017; doi:10.1038/leu.2017.138.</p>},
  author       = {Dimopoulos, M. A. and Kastritis, E and Terpos, E and Nahi, H and Goldschmidt, H. and Hillengass, J and Leleu, X and Beksac, Meral and Alsina, M and Oriol, Albert and Cavo, M. and Ocio, E. M. and Mateos, M. V. and O'Donnell, E K and Vij, R and Lokhorst, Henk M and van de Donk, Niels W C J and Cam-min, J. and Mark, Torrance and Turesson, I and Hansson, Markus and Jagannath, S. and Delforge, M and Kyriakou, Charalampia and Hari, P and Mellqvist, U. H. and Usmani, S Z and Dytfeld, D and Badros, Ashraf Z and Otero, P R and Shustik, C and Waller, D and Chng, W-J and Ozaki, Shoichi and de la Rubia, Javier and Eom, H S and Rosinol, L and Lahuerta, J. J. and Sureda, A and Kim, J. S. and Durie, B. G. M.},
  issn         = {1476-5551},
  keyword      = {Journal Article},
  language     = {eng},
  month        = {05},
  pages        = {2443--2448},
  publisher    = {Nature Publishing Group},
  series       = {Leukemia},
  title        = {Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : a multicenter IMWG study},
  url          = {http://dx.doi.org/10.1038/leu.2017.138},
  volume       = {31},
  year         = {2017},
}